कंपनी का अवलोकन
SOPHiA GENETICS SA operates as a cloud-native software technology enterprise within the healthcare sector, specifically focusing on the Health Information Services industry to provide advanced data analytics solutions. The company's core offering is the SOPHiA DDM platform, a cloud-native software solution designed for analyzing data and generating insights from multimodal data sets and various diagnostic modalities. In terms of scale, the enterprise holds a market capitalization of $348.31M, reported annual revenue of $77.27M, and employs a workforce of 415 individuals. These valuation and revenue metrics suggest that the company occupies a mid-cap position in the specialized health information services landscape, indicating a firm that has achieved significant operational scale yet remains sensitive to market fluctuations typical of smaller capitalization stocks. The combination of its specific industry focus and current financial size reflects an organization that is scaling its cloud-native technology infrastructure to serve the broader healthcare diagnostic ecosystem.
वित्तीय स्वास्थ्य
The company reported a trailing twelve-month revenue of $77.27M against a net income of $-78,999,000 and an EBITDA of $-69,168,000. The substantial gap between the positive revenue figure and the negative net income reveals a cost structure where operating expenses, including research and development or sales and marketing costs, have significantly exceeded gross profits, resulting in an overall loss. Free cash flow stands at $-16,462,000, which indicates that the company is currently burning cash rather than generating liquidity from its operations, implying limited financial flexibility for discretionary spending without external capital infusion. The gross margin is reported at 67.4%, suggesting that the software nature of the business allows for high revenue retention after direct costs, though this does not offset the broader operational inefficiencies. Conversely, the operating margin is -85.4% and the profit margin is -102.2%, figures that indicate severe operational leverage and a deep structural deficit relative to total revenue generation. The balance sheet shows cash assets of $70.29M compared to total debt of $63.02M, with a debt-to-equity ratio of 133.67, illustrating a highly leveraged position where debt obligations exceed equity capitalization. Despite the leverage, the current ratio of 1.96 indicates a robust short-term liquidity position, suggesting the company possesses sufficient current assets to cover its current liabilities nearly twice over. Return on Equity is -110.0% and Return on Assets is -27.9%, metrics that reveal management effectiveness is currently challenged by losses, as the company is generating negative returns on all invested capital bases.
मूल्यांकन आकलन
The trailing P/E ratio is listed as N/A due to the negative earnings, while the forward P/E is -8.68, a discrepancy that implies the market is pricing in future earnings recovery or sustained losses rather than current profitability. The price-to-book ratio is 7.06, indicating a significant market premium over the company's book value, which suggests investors are valuing the intangible assets, such as the proprietary SOPHiA DDM platform, far above their accounting book value. Alternative valuation metrics include a price-to-sales ratio of 4.51 and an EV/EBITDA of -4.93, which suggest that investors are relying on revenue multiples rather than earnings multiples to value the stock in the absence of profitability. The stock's 52-week high is $5.70 and the 52-week low is $2.58, meaning the current trading price sits below the high and above the low, reflecting a range-bound performance over the past year. The beta value is 1.04, which explains that the stock's price volatility is slightly higher than the broader market, indicating that price movements are moderately correlated with overall market trends but with added sensitivity to sector-specific risks.
Growth & Income
Revenue growth year-over-year is 22.4%, whereas earnings growth is N/A due to the reported net losses, implying that top-line expansion is occurring without corresponding profitability improvements in the current period. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the firm reinvests all available resources, including cash reserves, back into the business for growth initiatives rather than distributing income to shareholders. This non-dividend strategy is typical for growth-oriented technology companies that prioritize capital allocation toward platform development and market expansion over shareholder payouts. Overall, the growth and income profile of SOPHiA GENETICS SA is characterized by strong revenue acceleration coupled with a complete absence of current earnings or dividend income, positioning the stock purely as a growth vehicle for the healthcare technology sector.